Merck & Co. Inc. (MRK)

75.44
NYSE : Health Technology
Prev Close 75.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 52.83 / 80.19
Avg Volume 13.10M
Exchange NYSE
Shares Outstanding 2.60B
Market Cap 197.19B
EPS 0.90
P/E Ratio 60.66
Div & Yield 2.20 (2.62%)
European Medicines Agency Adopts Positive Opinion For KEYTRUDA® (pembrolizumab) Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lung Cancer

European Medicines Agency Adopts Positive Opinion For KEYTRUDA® (pembrolizumab) Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA ®,...

Stocks Trim Losses at Close of Trading

Stocks Trim Losses at Close of Trading

Stocks ended the day off their lows but still in the red Friday as tech share weakness overcame strong GDP data.

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Merck Beats Estimates and Raises Guidance, But Stock Plops 2%

Shares fell on Friday morning despite positive results for the second quarter.

Global Stocks Grind Higher as Trade Tension Ease: U.S. GDP in Focus

Global Stocks Grind Higher as Trade Tension Ease: U.S. GDP in Focus

With global trade tensions easing and U.S. corporate earnings continuing to impress, stocks are set to close out the week on solid footing, with gains possibly extended by a better-than-expected reading for U.S. economic growth over the second quarter.

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

U.S. stock futures rise modestly on Friday ahead of data on second-quarter GDP; Amazon's profit in the second quarter tops $2 billion; Intel shares fell despite the chipmaker beating earnings forecasts.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2018.

KEYTRUDA® (pembrolizumab) Is The First Anti-PD-1 Therapy Approved In China For Advanced Melanoma

KEYTRUDA® (pembrolizumab) Is The First Anti-PD-1 Therapy Approved In China For Advanced Melanoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA ®, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or...

REPEAT/KEYTRUDA® (pembrolizumab) Monotherapy Met A Primary Endpoint In The Phase 3 KEYNOTE-048 Trial, Significantly Improving OS As First-Line Therapy In Head And Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

REPEAT/KEYTRUDA® (pembrolizumab) Monotherapy Met A Primary Endpoint In The Phase 3 KEYNOTE-048 Trial, Significantly Improving OS As First-Line Therapy In Head And Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head...

KEYTRUDA® (pembrolizumab) Monotherapy Met A Primary Endpoint In The Phase 3 KEYNOTE-048 Trial, Significantly Improving OS As First-Line Therapy In Head And Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

KEYTRUDA® (pembrolizumab) Monotherapy Met A Primary Endpoint In The Phase 3 KEYNOTE-048 Trial, Significantly Improving OS As First-Line Therapy In Head And Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head...

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.

Merck Announces Fourth-Quarter 2018 Dividend

Merck Announces Fourth-Quarter 2018 Dividend

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-FORWARD Study Of Its Investigational HIV Therapy Doravirine

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-FORWARD Study Of Its Investigational HIV Therapy Doravirine

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Week 96 results from the Phase 3 DRIVE-FORWARD clinical trial evaluating the efficacy and safety of doravirine (DOR), the company's investigational non-nucleoside...

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

These blue chips pay shareholders handsomely in the form of dividends and share buybacks.

Merck Reinforces Commitment To Responsible Pricing

Merck Reinforces Commitment To Responsible Pricing

Merck (NYSE:MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing.

Four Great, Conservative Income Stocks

From Coca-Cola to Pfizer, these blue chips offer well-supported dividend payouts.

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Advanced Hepatocellular Carcinoma

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Advanced Hepatocellular Carcinoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

General Electric's Stock Is Attractive for the First Time in 2 Years: Jim Cramer

General Electric's Stock Is Attractive for the First Time in 2 Years: Jim Cramer

Jim Cramer says earnings could break the tie between the bulls and the bears -- unless China blinks. Here's the game plan for next week.

The New #22 Most Shorted Dow Component: Merck

The New #22 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 06/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck To Present New Data From Studies Of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, At AIDS 2018

Merck To Present New Data From Studies Of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, At AIDS 2018

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from the company are scheduled to be presented at the 22nd International AIDS Conference (AIDS 2018) taking place July 23-27 in Amsterdam.

LYNPARZA® (olaparib) Approved In Japan For BRCA-Mutated Metastatic Breast Cancer

LYNPARZA® (olaparib) Approved In Japan For BRCA-Mutated Metastatic Breast Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA ® (olaparib) tablets for use in patients with unresectable or...

Merck Announces Findings From WHO-led Study Of Investigational Heat-Stable Carbetocin For Preventing Excessive Bleeding After Childbirth

Merck Announces Findings From WHO-led Study Of Investigational Heat-Stable Carbetocin For Preventing Excessive Bleeding After Childbirth

Merck (NYSE: MRK), known as MSD outside the United States and Canada, through its Merck for Mothers initiative announced study results on an investigational heat-stable formulation of carbetocin for the prevention of excessive bleeding after childbirth,...

REPEAT/LYNPARZA® (olaparib) Significantly Delays Disease Progression In Phase 3 First-Line SOLO-1 Trial For Ovarian Cancer

REPEAT/LYNPARZA® (olaparib) Significantly Delays Disease Progression In Phase 3 First-Line SOLO-1 Trial For Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the randomized, double-blinded, placebo-controlled, Phase 3 SOLO-1 trial of LYNPARZA ® (olaparib) tablets.

Merck To Hold Second-Quarter 2018 Sales And Earnings Conference Call On July 27

Merck To Hold Second-Quarter 2018 Sales And Earnings Conference Call On July 27

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

LYNPARZA® (olaparib) Significantly Delays Disease Progression In Phase 3 First-Line SOLO-1 Trial For Ovarian Cancer

LYNPARZA® (olaparib) Significantly Delays Disease Progression In Phase 3 First-Line SOLO-1 Trial For Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the randomized, double-blinded, placebo-controlled, Phase 3 SOLO-1 trial of LYNPARZA ® (olaparib) tablets.

FDA Accepts Supplemental Biologics License Application For Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy In Advanced Melanoma

FDA Accepts Supplemental Biologics License Application For Merck's KEYTRUDA® (pembrolizumab) As Adjuvant Therapy In Advanced Melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Merck Presents New Data From The Comparative Trials With Sitagliptin (CompoSIT) Clinical Trial Program With JANUVIA® (sitagliptin)

Merck Presents New Data From The Comparative Trials With Sitagliptin (CompoSIT) Clinical Trial Program With JANUVIA® (sitagliptin)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA ® (sitagliptin).

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Jim Cramer says many stocks already reflect the worst-case scenarios, and that means he sees a lot of upside potential.

Novo Nordisk Stock Rises 4% Over 2 Sessions

Novo Nordisk Stock Rises 4% Over 2 Sessions

Pharma firm's new diabetes drug showed positive test results.

TheStreet Quant Rating: A- (Buy)